Mengzhen Lai

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Tao Zhang, Rong Qu, Shingpan Chan et al. · Molecular Cancer · 2020 · 143 citations · Full text

Medicine, Oncology, Pharmacology +14

Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations

Hao Chen, Mengzhen Lai, Tao Zhang et al. · Journal of Medicinal Chemistry · 2022 · 54 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo

Yingqiang Liu, Mengzhen Lai, Shan Li et al. · Cancer Science · 2021 · 51 citations · Full text

Medicine, Oncology, Pharmacology +14

Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR^{L858R/T790M/C797S})

Jiayi Shen, Tao Zhang, Sujie Zhu et al. · Journal of Medicinal Chemistry · 2019 · 50 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation

Tao Zhang, Zilu Pan, Jing Gao et al. · Signal Transduction and Targeted Therapy · 2024 · 34 citations · Full text

Medicine, Oncology, Pharmacology +17